In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots

Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment...

Full description

Saved in:
Bibliographic Details
Published inJournal of Nuclear Medicine Vol. 56; no. 8; pp. 1278 - 1284
Main Authors Hu, Kongzhen, Wang, Hongliang, Tang, Ganghua, Huang, Tingting, Tang, Xiaolan, Liang, Xiang, Yao, Shaobo, Nie, Dahong
Format Journal Article
LanguageEnglish
Published United States Society of Nuclear Medicine 01.08.2015
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with (18)F via the 4-nitrophenyl-2-(18)F-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-(18)F-fluoropropionyl-QD-RGD-BBN ((18)F-FP-QD-RGD-BBN). An in vivo biodistribution study of (18)F-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 μg/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD2) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH2-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the (18)F-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality (18)F-labeled QD probes with improved tumor-targeting efficacy.
AbstractList Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with (18)F via the 4-nitrophenyl-2-(18)F-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-(18)F-fluoropropionyl-QD-RGD-BBN ((18)F-FP-QD-RGD-BBN). An in vivo biodistribution study of (18)F-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 μg/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD2) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH2-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the (18)F-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality (18)F-labeled QD probes with improved tumor-targeting efficacy.
Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by -Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with ...via the 4-nitrophenyl-2-...-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-...-fluoropropionyl-QD-RGD-BBN (...-FP-QD-RGD-BBN). An in vivo biodistribution study of ...-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 ...g/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD...) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH...-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the ...-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality ...-labeled QD probes with improved tumor-targeting efficacy. (ProQuest: ... denotes formulae/symbols omitted.)
Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical applications. In this study, a dual receptor-targeting dual-modality PET/near-infrared fluorescence (NIRF) probe was developed for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. QDs were modified by β-Glu-RGD-BBN (RGD is arginine-glycine-aspartate acid, and BBN is bombesin) peptides and then labeled with ...via the 4-nitrophenyl-2-...-fluoropropionate prosthetic group. Cytotoxicity and cell-binding assay of QD-RGD-BBN were performed with PC-3 cells. In vivo dual-modality PET/NIRF imaging of prostate tumor-bearing mice was investigated using QD-RGD-BBN and 2-...-fluoropropionyl-QD-RGD-BBN (...-FP-QD-RGD-BBN). An in vivo biodistribution study of ...-FP-QD-RGD-BBN was performed on normal mice. QD-RGD-BBN exhibited strong red luminescence (600-800 nm) with the same maximum fluorescence wavelength (705 nm) as QD705 and slightly lower toxicity than that of QD705 in PC-3 cells at concentrations of greater than 30 ...g/mL. Uptake of QD-RGD-BBN in PC-3 cells showed no significant decrease in the presence of an excess amount of dimer arginine-glycine-aspartate acid (RGD...) or bombesin(7-14) (BBN) peptide but was blocked significantly in the presence of an excess amount of NH...-RGD-BBN. Dual-function PET/NIRF imaging is able to accurately assess the biodistribution and tumor-targeting efficacy of the ...-labeled functionalized QDs. The functionalized QD probe has great potential as a universal dual-targeting probe for detecting tumors in living subjects, opening up a new strategy for the development of multitargeting multimodality ...-labeled QD probes with improved tumor-targeting efficacy. (ProQuest: ... denotes formulae/symbols omitted.)
Author Tang, Ganghua
Nie, Dahong
Tang, Xiaolan
Wang, Hongliang
Hu, Kongzhen
Huang, Tingting
Liang, Xiang
Yao, Shaobo
Author_xml – sequence: 1
  givenname: Kongzhen
  surname: Hu
  fullname: Hu, Kongzhen
– sequence: 2
  givenname: Hongliang
  surname: Wang
  fullname: Wang, Hongliang
– sequence: 3
  givenname: Ganghua
  surname: Tang
  fullname: Tang, Ganghua
– sequence: 4
  givenname: Tingting
  surname: Huang
  fullname: Huang, Tingting
– sequence: 5
  givenname: Xiaolan
  surname: Tang
  fullname: Tang, Xiaolan
– sequence: 6
  givenname: Xiang
  surname: Liang
  fullname: Liang, Xiang
– sequence: 7
  givenname: Shaobo
  surname: Yao
  fullname: Yao, Shaobo
– sequence: 8
  givenname: Dahong
  surname: Nie
  fullname: Nie, Dahong
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26112023$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtLw0AUhQepaK3-ADcScOMmdWaSeS2ltVqoiFDFXZikkzolmdF5KPrrTUl14cLVhXu-c7mccwQGxhoFwCmCYywou9yY2KrVGCEyRoRzlu2BIUZEpJTi5wEYQkRRSggkh-DI-w2EkHLOD8AhpghhiLMheJ6b5Em_22QiTaVcMo2ySZfSrVXQZp1Is-pXd3YlGx0-k3kr11vlQ4eXZBZNFbQ1nfSlVslDlCbENpna4I_Bfi0br052cwQeZ9fLyW26uL-ZT64WaZVDElLByiwToq5yXisp8hwzmYs6UyXHSHBGJSawhLUUrKJYYFpDxiijZYlETZDIRuCiv_vq7FtUPhSt9pVqGmmUjb5AjEOCCcqyDj3_g25sdN3zWwpiBkneZTgCZzsqll26xavTrXSfxU9mHYB6oHLWe6fqXwTBYttL0fdSdL0UfS-dh_3xVDrIbXTBSd384_wGvKaR8Q
CODEN JNMEAQ
CitedBy_id crossref_primary_10_1007_s40820_018_0216_2
crossref_primary_10_1039_C7NR00298J
crossref_primary_10_1002_chem_202001402
crossref_primary_10_1021_acs_bioconjchem_1c00503
crossref_primary_10_2174_1381612826666200721001500
crossref_primary_10_1038_srep21959
crossref_primary_10_3390_biomedicines8090307
crossref_primary_10_3390_molecules29071537
crossref_primary_10_1016_j_fct_2017_07_006
crossref_primary_10_1016_j_tibtech_2017_08_006
crossref_primary_10_1002_cplu_202100171
crossref_primary_10_38124_ijisrt_IJISRT24NOV1416
crossref_primary_10_1007_s40336_018_0283_x
crossref_primary_10_1002_psc_3224
crossref_primary_10_1016_j_jconrel_2024_03_015
crossref_primary_10_1002_pep2_24205
crossref_primary_10_1002_advs_201600279
crossref_primary_10_3390_ijms24043455
crossref_primary_10_1515_ejnm_2016_0011
crossref_primary_10_3390_molecules28104122
crossref_primary_10_3390_ijms232213735
crossref_primary_10_1002_jbm_a_36862
crossref_primary_10_1016_j_jlumin_2019_01_011
crossref_primary_10_1016_j_actbio_2018_05_049
crossref_primary_10_1016_j_addr_2016_08_001
crossref_primary_10_1021_acs_chemrev_6b00290
crossref_primary_10_1021_acs_jmedchem_6b00025
crossref_primary_10_1142_S1793545823300082
crossref_primary_10_33483_jfpau_1323924
Cites_doi 10.1016/j.nucmedbio.2013.06.006
10.1128/AEM.67.10.4458-4463.2001
10.2174/187152006778226530
10.2217/17435889.3.1.83
10.1002/mc.10117
10.2967/jnumed.107.048009
10.1021/nl902659g
10.1007/s10967-013-2736-z
10.1007/s00726-010-0762-5
10.1021/nl052405t
10.1021/la303957y
10.2967/jnumed.107.043216
10.1289/ehp.10290
10.1016/j.biomaterials.2010.10.022
10.1158/0008-5472.CAN-06-1185
10.1038/nbt994
10.1289/ehp.8284
10.1126/science.1069040
10.1038/nbt920
10.1021/nl025673p
10.1016/j.nucmedbio.2011.10.009
10.1021/jm801285t
10.1073/pnas.152463399
ContentType Journal Article
Copyright 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Copyright Society of Nuclear Medicine Aug 1, 2015
Copyright_xml – notice: 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
– notice: Copyright Society of Nuclear Medicine Aug 1, 2015
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
4T-
8FD
FR3
K9.
M7Z
NAPCQ
P64
7QO
DOI 10.2967/jnumed.115.158873
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Docstoc
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biochemistry Abstracts 1
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
Biotechnology Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Technology Research Database
Docstoc
Biochemistry Abstracts 1
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Biotechnology Research Abstracts
DatabaseTitleList MEDLINE
Engineering Research Database
Nursing & Allied Health Premium
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2159-662X
1535-5667
EndPage 1284
ExternalDocumentID 3773075571
26112023
10_2967_jnumed_115_158873
Genre Research Support, Non-U.S. Gov't
Journal Article
Feature
GroupedDBID 123
18M
41~
5VS
96U
AAYXX
ACGFO
AEGXH
AIAGR
ALMA_UNASSIGNED_HOLDINGS
CITATION
GX1
N9A
RHI
TSM
U5U
W8F
---
-~X
.55
.GJ
29L
2WC
3O-
53G
5RE
7RV
7X7
88E
88I
8AF
8AO
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
8WZ
A6W
ABEFU
ABSQV
ABUWG
ACGOD
ACIWK
ACPRK
ADDZX
ADMOG
AENEX
AFFNX
AFKRA
AFOSN
AFRAH
AHMBA
AI.
ALIPV
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
DWQXO
E3Z
EBD
EBS
ECM
EIF
EJD
EMOBN
EX3
F5P
F9R
FYUFA
GNUQQ
H13
HCIFZ
HMCUK
I-F
IL9
INIJC
J5H
KQ8
L7B
LK8
M1P
M2P
M2Q
M7P
N4W
NAPCQ
NPM
OK1
P2P
P62
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R0Z
RNS
RWL
S0X
SJN
SV3
TAE
TR2
TUS
UKHRP
VH1
WH7
WOQ
WOW
X7M
YHG
YQJ
ZGI
ZXP
4T-
8FD
FR3
K9.
M7Z
P64
7QO
ID FETCH-LOGICAL-c405t-97b3399fc48fea94427a49f3eb8219876a250b0fa97c62926f077676bb19f5193
ISSN 0161-5505
IngestDate Fri Jul 11 15:23:23 EDT 2025
Mon Jun 30 10:37:02 EDT 2025
Thu Apr 03 07:08:26 EDT 2025
Tue Jul 01 01:45:13 EDT 2025
Thu Apr 24 23:12:23 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords quantum dots
integrin αvβ3
GRPR
fluorescence
PET
Language English
License 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-97b3399fc48fea94427a49f3eb8219876a250b0fa97c62926f077676bb19f5193
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://jnm.snmjournals.org/content/56/8/1278.full.pdf
PMID 26112023
PQID 1702705487
PQPubID 40808
PageCount 7
ParticipantIDs proquest_miscellaneous_1780525133
proquest_journals_1702705487
pubmed_primary_26112023
crossref_primary_10_2967_jnumed_115_158873
crossref_citationtrail_10_2967_jnumed_115_158873
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-08-00
2015-Aug
20150801
PublicationDateYYYYMMDD 2015-08-01
PublicationDate_xml – month: 08
  year: 2015
  text: 2015-08-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle Journal of Nuclear Medicine
PublicationTitleAlternate J Nucl Med
PublicationYear 2015
Publisher Society of Nuclear Medicine
Publisher_xml – name: Society of Nuclear Medicine
References 2021051712075857000_56.8.1278.10
2021051712075857000_56.8.1278.9
2021051712075857000_56.8.1278.11
2021051712075857000_56.8.1278.12
2021051712075857000_56.8.1278.5
2021051712075857000_56.8.1278.8
2021051712075857000_56.8.1278.2
2021051712075857000_56.8.1278.1
2021051712075857000_56.8.1278.4
2021051712075857000_56.8.1278.3
Tang (2021051712075857000_56.8.1278.16) 2012; 53
Tang (2021051712075857000_56.8.1278.7) 2011; 34
2021051712075857000_56.8.1278.18
2021051712075857000_56.8.1278.19
2021051712075857000_56.8.1278.14
2021051712075857000_56.8.1278.15
2021051712075857000_56.8.1278.17
2021051712075857000_56.8.1278.21
2021051712075857000_56.8.1278.22
2021051712075857000_56.8.1278.23
2021051712075857000_56.8.1278.24
2021051712075857000_56.8.1278.20
Tang (2021051712075857000_56.8.1278.6) 2012; 30
Zhang (2021051712075857000_56.8.1278.13) 2006; 47
2021051712075857000_56.8.1278.25
2021051712075857000_56.8.1278.26
2021051712075857000_56.8.1278.27
2021051712075857000_56.8.1278.28
References_xml – ident: 2021051712075857000_56.8.1278.18
  doi: 10.1016/j.nucmedbio.2013.06.006
– ident: 2021051712075857000_56.8.1278.26
  doi: 10.1128/AEM.67.10.4458-4463.2001
– ident: 2021051712075857000_56.8.1278.9
  doi: 10.2174/187152006778226530
– volume: 30
  start-page: 568
  year: 2012
  ident: 2021051712075857000_56.8.1278.6
  article-title: In situ visual imaging and in vivo distribution of head and neck squamous cell carcinoma in mice by near-infrared fluorescent quantum dots epidermal growth factor receptor monoclonal antibody probe
  publication-title: Hua Xi Kou Qiang Yi Xue Za Zhi.
– ident: 2021051712075857000_56.8.1278.1
  doi: 10.2217/17435889.3.1.83
– ident: 2021051712075857000_56.8.1278.11
  doi: 10.1002/mc.10117
– ident: 2021051712075857000_56.8.1278.14
  doi: 10.2967/jnumed.107.048009
– ident: 2021051712075857000_56.8.1278.25
  doi: 10.1021/nl902659g
– ident: 2021051712075857000_56.8.1278.19
  doi: 10.1007/s10967-013-2736-z
– ident: 2021051712075857000_56.8.1278.15
  doi: 10.1007/s00726-010-0762-5
– ident: 2021051712075857000_56.8.1278.2
  doi: 10.1021/nl052405t
– ident: 2021051712075857000_56.8.1278.23
  doi: 10.1021/la303957y
– ident: 2021051712075857000_56.8.1278.8
  doi: 10.2967/jnumed.107.043216
– volume: 34
  start-page: 765
  year: 2011
  ident: 2021051712075857000_56.8.1278.7
  article-title: Process of muti-targeted molecular imaging
  publication-title: Nucl Technol.
– ident: 2021051712075857000_56.8.1278.22
  doi: 10.1289/ehp.10290
– ident: 2021051712075857000_56.8.1278.24
  doi: 10.1016/j.biomaterials.2010.10.022
– ident: 2021051712075857000_56.8.1278.3
  doi: 10.1158/0008-5472.CAN-06-1185
– ident: 2021051712075857000_56.8.1278.5
  doi: 10.1038/nbt994
– volume: 53
  start-page: 1699
  year: 2012
  ident: 2021051712075857000_56.8.1278.16
  article-title: Radiosynthesis and preliminary evaluation of 18F-FB-PEG-BBN-beta-Glu-RGD-QD as a new targeted dual-receptor dual-modality probe for tumor imaging [abstract]
  publication-title: J Nucl Med.
– ident: 2021051712075857000_56.8.1278.28
  doi: 10.1289/ehp.8284
– ident: 2021051712075857000_56.8.1278.10
  doi: 10.1126/science.1069040
– ident: 2021051712075857000_56.8.1278.4
  doi: 10.1038/nbt920
– ident: 2021051712075857000_56.8.1278.20
  doi: 10.1021/nl025673p
– ident: 2021051712075857000_56.8.1278.12
  doi: 10.1016/j.nucmedbio.2011.10.009
– ident: 2021051712075857000_56.8.1278.17
– ident: 2021051712075857000_56.8.1278.27
  doi: 10.1021/jm801285t
– volume: 47
  start-page: 492
  year: 2006
  ident: 2021051712075857000_56.8.1278.13
  article-title: 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer
  publication-title: J Nucl Med.
– ident: 2021051712075857000_56.8.1278.21
  doi: 10.1073/pnas.152463399
SSID ssj0006888
ssj0062072
Score 2.3471563
Snippet Semiconductor quantum dots (QDs), after surface modification to provide water solubility and biocompatibility, have a promising future in biomedical...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1278
SubjectTerms Animals
Biocompatible Materials - chemistry
Bombesin - pharmacokinetics
Cancer
Cells
Copper Radioisotopes
Cytotoxicity
Female
Fluorescence
Male
Mice
Mice, Inbred BALB C
Neoplasm Transplantation
Neoplasms - diagnostic imaging
Nitrophenols - chemistry
Oligopeptides - chemistry
Peptides - chemistry
Positron-Emission Tomography
Prostatic Neoplasms - diagnostic imaging
Quantum Dots
Receptors, Bombesin - metabolism
Rodents
Semiconductors
Spectrometry, Fluorescence
Tissue Distribution
Tumors
Title In Vivo Cancer Dual-Targeting and Dual-Modality Imaging with Functionalized Quantum Dots
URI https://www.ncbi.nlm.nih.gov/pubmed/26112023
https://www.proquest.com/docview/1702705487
https://www.proquest.com/docview/1780525133
Volume 56
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgSIgXND5XNiYj8USVkTixnTyisa6FdWhSCn2LnC821CVoNHvoX78720lavjR4SVsnuVS-X-7LvjtCXnt-UOZhxp0sKDi2MAsc5frKkYLLCDWMUJgoPD0V41nwYc7n_V5VnV2yTA-y1W_zSv6HqzAGfMUs2X_gbEcUBuA78BeOwGE43orHk2r4-eK6Hh4i666G7xu1cGK9tbtNPdRD0zo31vbk0vQk0sHXEWg0Ewi8WIHVedbAHDeXYFGb2k6txdrnji3Mpo8MG010a_K60BP4iGsRhXGjpUddfV2d94lmX2xgelxj4rCyClPHDMyJY_g8b1RPxY7HuMe_VbA2PuHxbndcF7IUnoN-0LrMNcXELbbCNQHqMdPRxyrj9ufPgp5FApeav1VALAexzw88DuLS77Vau5J_-ikZzU5OkvhoHt8l9xh4E9jo4uNZX1RehLo9afdHzeI3PuLtLw_YNF_-4JNo2yTeJg8te-g7g5BH5E5RPSb3p5ZFT8h8UlEECjVAoZtAoQAUugEUaoFCESh0EyjUAoUiUJ6S2egoPhw7tqUGvIsuXzqRTH0wScssCMtCRUHApAqi0i_SkGH4SSgwiVO3VJHMBIuYKHW5J5GmXlSisf-MbFV1VewQmhdK5j5QdV2gJmUqPaBShmWuOON5PiBuO1NJZuvNY9uTRQJ-J05uYiYXfFCemMkdkDfdLd9NsZW_XbzXTn9i38kfiSddJl30wgfkVXcaJCYug6mqqBu8Btt4YF-jAXlu2NY9jQnwP8CMfXGLu3fJgx7ve2RredUUL8FCXab7Gl8300OP-w
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=In+Vivo+Cancer+Dual-Targeting+and+Dual-Modality+Imaging+with+Functionalized+Quantum+Dots&rft.jtitle=The+Journal+of+nuclear+medicine+%281978%29&rft.au=Hu%2C+Kongzhen&rft.au=Wang%2C+Hongliang&rft.au=Tang%2C+Ganghua&rft.au=Huang%2C+Tingting&rft.date=2015-08-01&rft.issn=0161-5505&rft.volume=56&rft.issue=8&rft.spage=1278&rft.epage=1278&rft_id=info:doi/10.2967%2Fjnumed.115.158873&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-5505&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-5505&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-5505&client=summon